Share on LinkedInShare on LinkedIn

ARTICLE · 11 JUNE 2012

Federal Circuit Reaffirms Broad And Expansive Obviousness Inquiry, Rejecting A Formal Burden-Shifting Framework

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, Nos. 11-1399, -1409 (Fed. Cir. Apr. 16, 2012)

United StatesIntellectual Property

This article previously appeared in Last Month at the Federal Circuit, May, 2012.

Judges: Newman, O'Malley (author), Reyna

[Appealed from D. Del., Judge Robinson]

In In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, Nos. 11-1399, -1409 (Fed. Cir. Apr. 16, 2012), the Federal Circuit reversed the district court's obviousness finding, holding that it failed to consider the lack of a known pharmokinetic/pharmodynamic ("PK/PD") relationship for the claimed drug formulation, thereby erring in assessing the importance of the teachings of the prior art. The Court also affirmed the rejection of the defendants' alternate argument that the asserted patents were invalid for failure to disclose the best mode, stating that the evidence supported a finding that the patents enable one of ordinary skill in the art to practice the inventor's preferred dew points.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from